Patients with Crohn’s disease are now likely to get National Health Service access to Takeda’s biologic Entyvio in England and Wales following a u-turn by the National Institute for Health and Care Excellence.

The Institute has published final draft guidance endorsing the drug as an option to treat patients with moderate to severely active Crohn’s disease if treatment with a tumour necrosis factor alpha inhibitor has failed or can’t be tolerated.

For more details, go to: http://www.pharmatimes.com/Article/15-07-10/NICE_U-turn_as_Entyvio_is_backed_for_Crohn_s.aspx